Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery

M. Braga, L. Gianotti, O. Gentilini, A. Vignali, V. Di Carlo

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background/Aims: This trial was designed to quantify the production of new red blood cells (RBCs) after treatment with recombinant human erythropoietin (rHuEPO). Materials and Method: Twenty anemic patients with gastric or colorectal cancer were prospectively studied. The control group (n = 10) underwent surgery without delay. The experimental group (n = 10) received treatment with 500 U/kg of r-HuEPO divided in three doses which were administrated as follows: 300 U/kg 12 days before surgery and 100 U/kg 4 and 8 days later. Results: RBC gain was 210 ± 75 mL in the experimental group which received treatment. The erythropoietic response was similar after 300 U/kg (59 ± 36 mL) or 100 U/kg 75 ± 24 mL). No correlation was found between RBC gain and age (r = 0.18) or baseline levels of erythropoietin (r = 0.08), hemoglobin (r = O.O6), erythrocytes (r = 0.01), reticulocytes (r = 0.01), iron (r = 0.28) and ferritin (r = 0.08). One treated patient in the experimental group was transfused with allogeneic blood (2 units) versus 5 control patients (overall 13 units) (p = 0.06). Conclusion: Preoperative treatment with r-HuEPO improved erythropoiesis and reduced allogeneic transfusions in anemic cancer patients. No significant difference in RBC gains was noted between r-HuEPO administration at 300 U/kg and r-HuEPO administration at 100 U/kg. This result suggests a possible dose reduction for future trials.

Original languageEnglish
Pages (from-to)685-690
Number of pages6
JournalHepato-Gastroenterology
Volume44
Issue number15
Publication statusPublished - 1997

Fingerprint

Erythropoietin
Erythrocytes
Neoplasms
Erythropoiesis
Reticulocytes
Therapeutics
Ferritins
Ambulatory Surgical Procedures
Stomach Neoplasms
Colorectal Neoplasms
Hemoglobins
Iron
Control Groups

Keywords

  • Anemia
  • Blood transfusion
  • Cancer
  • Cost/benefit analysis
  • Erythropoiesis
  • Erythropoietin
  • Surgery

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery. / Braga, M.; Gianotti, L.; Gentilini, O.; Vignali, A.; Di Carlo, V.

In: Hepato-Gastroenterology, Vol. 44, No. 15, 1997, p. 685-690.

Research output: Contribution to journalArticle

@article{80ee8dad17d94d06b5bd2300dec7a957,
title = "Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery",
abstract = "Background/Aims: This trial was designed to quantify the production of new red blood cells (RBCs) after treatment with recombinant human erythropoietin (rHuEPO). Materials and Method: Twenty anemic patients with gastric or colorectal cancer were prospectively studied. The control group (n = 10) underwent surgery without delay. The experimental group (n = 10) received treatment with 500 U/kg of r-HuEPO divided in three doses which were administrated as follows: 300 U/kg 12 days before surgery and 100 U/kg 4 and 8 days later. Results: RBC gain was 210 ± 75 mL in the experimental group which received treatment. The erythropoietic response was similar after 300 U/kg (59 ± 36 mL) or 100 U/kg 75 ± 24 mL). No correlation was found between RBC gain and age (r = 0.18) or baseline levels of erythropoietin (r = 0.08), hemoglobin (r = O.O6), erythrocytes (r = 0.01), reticulocytes (r = 0.01), iron (r = 0.28) and ferritin (r = 0.08). One treated patient in the experimental group was transfused with allogeneic blood (2 units) versus 5 control patients (overall 13 units) (p = 0.06). Conclusion: Preoperative treatment with r-HuEPO improved erythropoiesis and reduced allogeneic transfusions in anemic cancer patients. No significant difference in RBC gains was noted between r-HuEPO administration at 300 U/kg and r-HuEPO administration at 100 U/kg. This result suggests a possible dose reduction for future trials.",
keywords = "Anemia, Blood transfusion, Cancer, Cost/benefit analysis, Erythropoiesis, Erythropoietin, Surgery",
author = "M. Braga and L. Gianotti and O. Gentilini and A. Vignali and {Di Carlo}, V.",
year = "1997",
language = "English",
volume = "44",
pages = "685--690",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "15",

}

TY - JOUR

T1 - Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery

AU - Braga, M.

AU - Gianotti, L.

AU - Gentilini, O.

AU - Vignali, A.

AU - Di Carlo, V.

PY - 1997

Y1 - 1997

N2 - Background/Aims: This trial was designed to quantify the production of new red blood cells (RBCs) after treatment with recombinant human erythropoietin (rHuEPO). Materials and Method: Twenty anemic patients with gastric or colorectal cancer were prospectively studied. The control group (n = 10) underwent surgery without delay. The experimental group (n = 10) received treatment with 500 U/kg of r-HuEPO divided in three doses which were administrated as follows: 300 U/kg 12 days before surgery and 100 U/kg 4 and 8 days later. Results: RBC gain was 210 ± 75 mL in the experimental group which received treatment. The erythropoietic response was similar after 300 U/kg (59 ± 36 mL) or 100 U/kg 75 ± 24 mL). No correlation was found between RBC gain and age (r = 0.18) or baseline levels of erythropoietin (r = 0.08), hemoglobin (r = O.O6), erythrocytes (r = 0.01), reticulocytes (r = 0.01), iron (r = 0.28) and ferritin (r = 0.08). One treated patient in the experimental group was transfused with allogeneic blood (2 units) versus 5 control patients (overall 13 units) (p = 0.06). Conclusion: Preoperative treatment with r-HuEPO improved erythropoiesis and reduced allogeneic transfusions in anemic cancer patients. No significant difference in RBC gains was noted between r-HuEPO administration at 300 U/kg and r-HuEPO administration at 100 U/kg. This result suggests a possible dose reduction for future trials.

AB - Background/Aims: This trial was designed to quantify the production of new red blood cells (RBCs) after treatment with recombinant human erythropoietin (rHuEPO). Materials and Method: Twenty anemic patients with gastric or colorectal cancer were prospectively studied. The control group (n = 10) underwent surgery without delay. The experimental group (n = 10) received treatment with 500 U/kg of r-HuEPO divided in three doses which were administrated as follows: 300 U/kg 12 days before surgery and 100 U/kg 4 and 8 days later. Results: RBC gain was 210 ± 75 mL in the experimental group which received treatment. The erythropoietic response was similar after 300 U/kg (59 ± 36 mL) or 100 U/kg 75 ± 24 mL). No correlation was found between RBC gain and age (r = 0.18) or baseline levels of erythropoietin (r = 0.08), hemoglobin (r = O.O6), erythrocytes (r = 0.01), reticulocytes (r = 0.01), iron (r = 0.28) and ferritin (r = 0.08). One treated patient in the experimental group was transfused with allogeneic blood (2 units) versus 5 control patients (overall 13 units) (p = 0.06). Conclusion: Preoperative treatment with r-HuEPO improved erythropoiesis and reduced allogeneic transfusions in anemic cancer patients. No significant difference in RBC gains was noted between r-HuEPO administration at 300 U/kg and r-HuEPO administration at 100 U/kg. This result suggests a possible dose reduction for future trials.

KW - Anemia

KW - Blood transfusion

KW - Cancer

KW - Cost/benefit analysis

KW - Erythropoiesis

KW - Erythropoietin

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=0030960205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030960205&partnerID=8YFLogxK

M3 - Article

C2 - 9222672

AN - SCOPUS:0030960205

VL - 44

SP - 685

EP - 690

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 15

ER -